Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial

Supplementary Materials for "Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial".《司培克单抗（stapokibart，CM310）治疗中重度特应性皮炎成人患者的疗效与安全性：一项多中心、随机、双盲、安慰剂对照III期临床试验》的补充材料